S607 One-Time Colorectal Cancer Screening With Next-Generation mt-sDNA vs FIT: Clinical and Economic Impact Using a Comprehensive Cost-Calculator Economic Model

Introduction: Colorectal cancer (CRC) remains one of the leading causes of cancer-related morbidity and mortality in the US. Multiple stool-based CRC screening strategies with varying intervals are currently recommended by the United States Preventive Services Task Force. With the recent introduction of triennial screening with the next-generation multi-target stool DNA (ng mt-sDNA) test, it is timely to explore its estimated impact compared to annual screening with the fecal immunochemical test (FIT), using predicted real-world adherence and performance characteristics from clinical trials. Many prior analyses assumed perfect adherence to both screening and follow-up colonoscopy, which can lead to biased results. Methods: A cohort-based model was developed with prevalence of advanced precancerous lesions (APL) and CRC obtained from published clinical trials. A hypothetical cohort of 1 million average-risk individuals was modeled to simulate the estimated outcomes from one round of ng mt-sDNA versus FIT screening. Test performance was based on the BLUE-C clinical trial with ng mt-sDNA compared to FIT sensitivity for CRC and APL. Based on published literature, real-world adherence was modeled at 71.3% for ng mt-sDNA and 31.8% for FIT completion, and 72.1% and 46.0%, for follow-up colonoscopy. Screening and treatment costs were included based on reported literature. Outcomes included the number of detected CRC and APL cases, CRC cases averted through APL detection, and associated costs for each screening strategy. Results: The model predicted significantly more patients screened with ng mt-sDNA compared to FIT (713,000 vs 318,000), with 5.7-fold higher achievement of HEDIS® quality targets over 3 years. ng mt-sDNA detected 5.5 times more APL (21,701 vs 3,328) and 3.7 times more CRC cases (2,090 vs 440) than FIT screening. CRC cases averted were 1,736 with ng mt-sDNA, 5.5 times higher than FIT (266 cases). Finally, ng mt-sDNA reduced CRC treatment costs by 3% and total (screening and treatment) costs by 2% ($1,388 M vs $1,423 M) compared to FIT. Conclusion: This analysis of one-time screening suggests that ng mt-sDNA can more effectively detect and avert CRC cases and related costs as compared to FIT, due to differences in performance, completion, and follow up colonoscopy rates. Expanded use of ng mt-sDNA CRC screening tests represents a practical, scalable strategy to improve clinical and economic outcomes achieved through noninvasive CRC screening.